AU2014363428B2 - A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder - Google Patents

A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder Download PDF

Info

Publication number
AU2014363428B2
AU2014363428B2 AU2014363428A AU2014363428A AU2014363428B2 AU 2014363428 B2 AU2014363428 B2 AU 2014363428B2 AU 2014363428 A AU2014363428 A AU 2014363428A AU 2014363428 A AU2014363428 A AU 2014363428A AU 2014363428 B2 AU2014363428 B2 AU 2014363428B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
dioxolo
piperazin
dopamine
methanesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014363428A
Other languages
English (en)
Other versions
AU2014363428A1 (en
Inventor
Agnes Auclair
Paul Moser
Pierre Sokoloff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of AU2014363428A1 publication Critical patent/AU2014363428A1/en
Application granted granted Critical
Publication of AU2014363428B2 publication Critical patent/AU2014363428B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014363428A 2013-12-13 2014-12-12 A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder Ceased AU2014363428B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306726 2013-12-13
EP13306726.4 2013-12-13
PCT/EP2014/077635 WO2015086836A1 (en) 2013-12-13 2014-12-12 A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder

Publications (2)

Publication Number Publication Date
AU2014363428A1 AU2014363428A1 (en) 2016-06-23
AU2014363428B2 true AU2014363428B2 (en) 2019-09-12

Family

ID=49883003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014363428A Ceased AU2014363428B2 (en) 2013-12-13 2014-12-12 A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder

Country Status (29)

Country Link
US (1) US10028948B2 (https=)
EP (1) EP3079688B1 (https=)
JP (1) JP6419826B2 (https=)
KR (1) KR102280530B1 (https=)
CN (1) CN105792824B (https=)
AU (1) AU2014363428B2 (https=)
BR (1) BR112016012552A8 (https=)
CA (1) CA2932791C (https=)
CY (1) CY1119907T1 (https=)
DK (1) DK3079688T3 (https=)
ES (1) ES2657706T3 (https=)
HR (1) HRP20180323T8 (https=)
HU (1) HUE036035T2 (https=)
IL (1) IL245996B (https=)
LT (1) LT3079688T (https=)
MA (1) MA39076A1 (https=)
MX (1) MX372922B (https=)
MY (1) MY172937A (https=)
NO (1) NO3079688T3 (https=)
NZ (1) NZ720868A (https=)
PL (1) PL3079688T3 (https=)
PT (1) PT3079688T (https=)
RS (1) RS56931B1 (https=)
RU (2) RU2019104946A (https=)
SA (1) SA516371298B1 (https=)
SI (1) SI3079688T1 (https=)
TN (1) TN2016000213A1 (https=)
UA (1) UA117271C2 (https=)
WO (1) WO2015086836A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53866B1 (sr) 2008-07-16 2015-08-31 Richter Gedeon Nyrt. Farmaceutske formulacije koje sadrže ligande dopaminskih receptora
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
TWI884984B (zh) * 2019-09-11 2025-06-01 英商牛津生物力學公眾有限公司 診斷染色體標記
KR20220021157A (ko) 2020-08-13 2022-02-22 원광대학교산학협력단 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539281A1 (fr) * 1991-10-23 1993-04-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux dérivés de naphtamides, leur procédé de préparation et leur application dans le domaine thérapeutique
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
WO2000021951A1 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465A1 (fr) * 2009-09-01 2011-03-04 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
WO2011150380A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012168411A1 (fr) * 2011-06-09 2012-12-13 Pierre Fabre Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012157463A1 (en) * 2011-05-13 2012-11-22 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539281A1 (fr) * 1991-10-23 1993-04-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux dérivés de naphtamides, leur procédé de préparation et leur application dans le domaine thérapeutique
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
WO2000021951A1 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465A1 (fr) * 2009-09-01 2011-03-04 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
WO2011150380A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012168411A1 (fr) * 2011-06-09 2012-12-13 Pierre Fabre Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KING, B. H. et al. "Double-blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children with Autistic Disorder" J. Am. Acad. Child Adolesc. Psychiatry (2001) vol. 40, no. 6, pages 658-665 *
LEMONNIER, E. "A randomised controlled trial of bumetanide in the treatment of autism in children" Transl. Psychiatry (2012) vol. 2, no. 12, page e202 *
MICHALON, A. et al. "Chronic Pharmacological mGlu5 Inhibtion Corrects Fragile X in Adult Mice" Neuron (2012) vol. 74, no. 1, pages 49-56 *
YOCHUM, C. L. et al. "Differential development of central dopaminergic and serotonergic systems in BALB/c and C57BL/6J mice" Brain Research (2010) vol. 1349 pages 97-104 *

Also Published As

Publication number Publication date
WO2015086836A1 (en) 2015-06-18
CY1119907T1 (el) 2018-06-27
MY172937A (en) 2019-12-16
ES2657706T3 (es) 2018-03-06
RU2686110C1 (ru) 2019-04-24
IL245996A0 (en) 2016-07-31
IL245996B (en) 2018-11-29
US10028948B2 (en) 2018-07-24
HRP20180323T1 (hr) 2018-04-06
RU2019104946A (ru) 2019-04-01
EP3079688B1 (en) 2017-11-22
DK3079688T3 (da) 2018-01-29
MX372922B (es) 2020-04-27
EP3079688A1 (en) 2016-10-19
JP2016540000A (ja) 2016-12-22
HRP20180323T8 (hr) 2019-01-25
KR102280530B1 (ko) 2021-07-21
JP6419826B2 (ja) 2018-11-07
HUE036035T2 (hu) 2018-06-28
CA2932791C (en) 2021-11-09
CN105792824A (zh) 2016-07-20
NZ720868A (en) 2022-04-29
TN2016000213A1 (en) 2017-10-06
NO3079688T3 (https=) 2018-04-21
AU2014363428A1 (en) 2016-06-23
US20160303117A1 (en) 2016-10-20
PT3079688T (pt) 2018-02-28
KR20160088886A (ko) 2016-07-26
CA2932791A1 (en) 2015-06-18
PL3079688T3 (pl) 2018-05-30
HK1223563A1 (zh) 2017-08-04
UA117271C2 (uk) 2018-07-10
BR112016012552A8 (pt) 2022-11-08
LT3079688T (lt) 2018-02-12
MA39076A1 (fr) 2017-05-31
MX2016007612A (es) 2016-09-09
SA516371298B1 (ar) 2018-06-07
RS56931B1 (sr) 2018-05-31
SI3079688T1 (en) 2018-03-30
CN105792824B (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
AU2014363428B2 (en) A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder
US20220202798A1 (en) Use of pridopidine for the treatment of fragile x syndrome
US20250235443A1 (en) Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
WO2016192687A1 (en) New use of inhibitor of cystine-glutamate transporter
OA17906A (en) A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder.
HK1223563B (zh) 色酮衍生物作为多巴胺d3受体拮抗剂用於治疗自闭症谱系障碍的用途
US20180289655A1 (en) Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases
RU2812786C2 (ru) Применение ролуперидона для лечения негативных симптомов и заболеваний, повышения нейропластичности и содействия нейрозащите
TW201035081A (en) Novel pharmaceutical composition for treatment of schizophrenia
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
Fonteneau et al. Tilted striatofugal balance and beneficial effects of facilitating mGlu4 receptor activity in the Fmr1-/-mouse model of Fragile X Syndrome
TW202307217A (zh) 用於診斷及治療於染色體2的2:107,510,000至107,540,000位點具有單一核苷酸多型性的個體的方法
TW202132278A (zh) 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途
Tsuboi et al. Clinical Diagnosis of Familial Atypical Parkinsonian Disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired